These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 25150193)

  • 41. Comparison of Drug Approvals in Europe Versus the United States: An Analysis of Discrepancies Between Drug Products Reviewed by EMA and FDA.
    Makuch RW; Shi R
    Ther Innov Regul Sci; 2014 May; 48(3):362-366. PubMed ID: 30235531
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FDA and EMA Approvals of New Breast Cancer Drugs-A Comparative Regulatory Analysis.
    Leo CP; Hentschel B; Szucs TD; Leo C
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32069837
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
    Davit BM; Kanfer I; Tsang YC; Cardot JM
    AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of published core outcome sets with outcomes recommended in regulatory guidance from the US Food and Drug Administration and European Medicines Agency: cross sectional analysis.
    Saldanha IJ; Dodd S; Fish R; Gorst SL; Hall DA; Jacobsen P; Kirkham JJ; Trepel D; Williamson PR
    BMJ Med; 2022; 1(1):e000233. PubMed ID: 36936602
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice.
    Trotta F; Leufkens HG; Schellens JH; Laing R; Tafuri G
    J Clin Oncol; 2011 Jun; 29(16):2266-72. PubMed ID: 21537038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmaceuticals Licensing and Reimbursement in the European Union, United States, and Japan.
    Oye KA; Eichler HG; Hoos A; Mori Y; Mullin TM; Pearson M
    Clin Pharmacol Ther; 2016 Dec; 100(6):626-632. PubMed ID: 27618128
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Twenty-year History and Future Challenges in Transparency Enhancement of Review Process for Approval: Focus on Public Release of Review Reports regarding New Drugs and Medical Devices].
    Morimoto K; Kawasaki S; Yoshida Y
    Yakushigaku Zasshi; 2015; 50(1):64-77. PubMed ID: 26427100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency.
    Sellers JW; Mihaescu CM; Ayalew K; Kronstein PD; Yu B; Ning YM; Rodriguez M; Williams L; Khin NA
    Ther Innov Regul Sci; 2022 Sep; 56(5):753-764. PubMed ID: 35610469
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preclinical efficacy in therapeutic area guidelines from the U.S. Food and Drug Administration and the European Medicines Agency: a cross-sectional study.
    Langhof H; Chin WWL; Wieschowski S; Federico C; Kimmelman J; Strech D
    Br J Pharmacol; 2018 Nov; 175(22):4229-4238. PubMed ID: 30153701
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The New Drug Lag: EU Lags in Review Times of Monoclonal Antibodies.
    Sharma V; Deore VD; Deore SV; Martin IG
    Ther Innov Regul Sci; 2020 Jul; 54(4):770-774. PubMed ID: 32557295
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) perspective on cardiovascular Polypill: A multidimensional concept.
    Mogielnicki M; Swieczkowski D; Bachorski W; Zuk G; Gilis-Malinowska N; Zarzeka A; Merks P; Gruchala M; Jaguszewski M
    Cardiol J; 2016; 23(5):515-517. PubMed ID: 27723064
    [No Abstract]   [Full Text] [Related]  

  • 54. Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talking to Each Other?
    Teixeira T; Kweder SL; Saint-Raymond A
    Clin Pharmacol Ther; 2020 Mar; 107(3):507-513. PubMed ID: 31449664
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
    Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
    BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of Good Clinical Practice Inspection Processes for Marketing Applications Between the United States Food and Drug Administration and the European Medicines Agency.
    Ayalew K; Ning YM; Foringer MJ; Leibenhaut S; Sellers JW; Yu B; Kronstein PD; Higgerson A; Mihaescu C; Rodriguez M; Williams L; Khin NA
    Ther Innov Regul Sci; 2023 Jan; 57(1):79-85. PubMed ID: 35972722
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency.
    Dörr P; Wadworth A; Wang T; McAuslane N; Liberti L
    Ther Innov Regul Sci; 2016 Nov; 50(6):734-742. PubMed ID: 30231740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
    Senderowicz AM; Pfaff O
    Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.
    Zeitoun JD; Baron G; Vivot A; Atal I; Downing NS; Ross JS; Ravaud P
    Int J Cancer; 2018 Jan; 142(2):414-423. PubMed ID: 28929484
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.
    Romero K; Clay R; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S5-9. PubMed ID: 26224771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.